<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572923</url>
  </required_header>
  <id_info>
    <org_study_id>BRONC 45, 1.5</org_study_id>
    <nct_id>NCT00572923</nct_id>
  </id_info>
  <brief_title>Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans</brief_title>
  <acronym>BRONC 45 15</acronym>
  <official_title>Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our group has shown that the omission of elective nodal irradiation on the basis of CT scans&#xD;
      in patients with LD-SCLC lead to a higher than expected isolated nodal recurrence in the&#xD;
      ipsilateral supraclavicular area. We have previously also shown that selective mediastinal&#xD;
      nodal radiation on basis of FDG-PET scans in NSCLC is safe and reduces the radiation fields&#xD;
      and hence toxicity. As the accuracy of FDG-PET scans is also in SCLC higher than CT, we will&#xD;
      investigate the safety of selective nodal irradiation in LD-SCLC patients treated with&#xD;
      concurrent chemo-radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients (see below) will receive radiotherapy to the primary tumor and the&#xD;
      initially involved mediastinal lymph nodes on FDG-PET scan to a dose of 45 Gy in 30 fractions&#xD;
      in 3 weeks (1.5 Gy BID with minimum 6 h interfraction interval).&#xD;
&#xD;
      Dose-constraints: MLD &gt; 20 Gy. In that case, CT-based replanning will be done after 1 week of&#xD;
      treatment and shrinking field techniques will be used if appropriate.&#xD;
&#xD;
      The radiation doses will be specified according to ICRU 50. Lung density corrections will be&#xD;
      applied, as well as all standard QA procedures. Technical requirements are the same as in&#xD;
      standard practice at MAASTRO clinic.&#xD;
&#xD;
      Radiotherapy shall start during the first cycle of carboplatin and etoposide chemotherapy.&#xD;
&#xD;
      Chemotherapy (standard schedule in the Comprehensive Cancer Centre Limburg region):&#xD;
&#xD;
        -  carboplatin AUC 5 day 1&#xD;
&#xD;
        -  etoposide 120 mg/m2 days 1-3&#xD;
&#xD;
      Q 3 weeks; 5 cycles&#xD;
&#xD;
      In patients with no progression and a WHO PS 0-2, after the completion of chemotherapy, PCI&#xD;
      will be given (25 Gy in 10 fractions, QD)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>isolated Nodal Recurrences</measure>
    <time_frame>18 months post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free interval</measure>
    <time_frame>18 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea (CTCAE 3.0)</measure>
    <time_frame>18 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dysphagia (CTCAE 3.0)</measure>
    <time_frame>18 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patterns of recurrence</measure>
    <time_frame>18 months post-treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Inclusion criteria&#xD;
Histological or cytological proven SCLC&#xD;
UICC stage I-III, &quot;limited disease&quot;&#xD;
Performance status 0-2&#xD;
FeV1 and DLCO at least 30% of age-predicted value&#xD;
Exclusion criteria:&#xD;
Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)&#xD;
stage IV&#xD;
performance status 3 or more&#xD;
FeV 1 or DLCO&lt; 30% of the age-predicted value</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Histological or cytological proven SCLC&#xD;
&#xD;
          -  UICC stage I-III, &quot;limited disease&quot;&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  FeV 1 and DLCO at least 30% of the age-predicted value&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proven SCLC&#xD;
&#xD;
          -  UICC stage I-III, &quot;limited disease&quot;&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  FeV 1 and DLCO at least 30% of the age-predicted value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not SCLC or mixed SCLC and other histologies (e.g. non-small cell lung carcinoma)&#xD;
&#xD;
          -  UICC stage IV&#xD;
&#xD;
          -  Performance status 3 or more&#xD;
&#xD;
          -  FeV 1 and DLCO &lt; 30% of the age-predicted value&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO clinic, Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic, Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>MAASTRO clinic</name_title>
    <organization>MAASTRO clinic</organization>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>LD-SCLC</keyword>
  <keyword>stage I-III small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

